Anthracyclines, such as doxorubicin, and monoclonal antibodies, such as trastuzumab, are compounds of wide clinical use as cytotoxic chemotherapy as they. Cardiotoxicidad asociada a trastuzumab en la práctica clínica asistencial Neutropenia inducida por dosis terapéuticas de metronidazol intravenoso. cardiotoxicidad inducida por quimioterapia, además de hacer una síntesis de los diferentes . tion (anthracyclines, trastuzumab, tyrosine kinase inhibitors.
|Published (Last):||11 November 2004|
|PDF File Size:||8.84 Mb|
|ePub File Size:||10.99 Mb|
|Price:||Free* [*Free Regsitration Required]|
What is QT interval prolongation? A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
Introducing a new entity: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. Tiribelli M, Medeot M. The data were obtained through the analysis of the medical records of the patients attended at the outpatient clinic from January to December Expert Rev Anticancer Ther. Am J Clin Pathol. Am J Cardiovasc Drugs. Electrocardiographic changes simulating acute myocardial infarction or ischemia associated with combination chemotherapy with etoposide, cisplatin, and cardiotoxiciddad.
Regarding the histological classification of cancer, 21 patients presented Ductal Invasive Carcinoma, figure 1 shows the main histological types presented by the patients. J Ttrastuzumab Intern Med.
Moreira C, Kaklamani V. Identify the main adverse reactions presented by patients with HER2 positive breast cancer from an outpatient clinic specialized in chemotherapy in the city of Caruaru-PE, after the use of Trastuzumab. Cardioprotective interventions for cancer patients receiving anthracyclines. Adverse cardio- vascular effects of vinorelbine in non-small-cell bronchial carcinoma.
Sedentary behavior, physical activity, and the metabolic syndrome among U. Teastuzumab cardiotoxicity with tyrosine kinase inhibitors.
Preclinical evaluation of potential nilotinib cardiotoxicity. Herceptin and the heart – a molecular modifier of cardiac failure. Quantification of pericardial effusions by echocardiography and computed tomography.
In order to inhibit the proliferation of cancer cells, the cell cycle is one of the main foci in the action of antineoplastic agents. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: With respect to clinical staging, Santos et al 8 demonstrated a greater number of patients with stage III and II, corroborating the data collected in this study, presenting 13 patients in stage III and 9 patients with stage II as shown in figure 3.
Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery. Korean J Intern Med. Cardiovascular effects of systemic cancer treatment. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.
There was a problem providing the content you requested
J Am Soc Echocardiogr. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
Curr Treat Options Cardiovasc Med. Trastuzumab and heart failure. Outcome of children cured of acute lymphoblastic leukemia. Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with cardiotoxicidxd. Clin Adv Hematol Oncol. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy.
Muerte súbita debida a cardiotoxicidad aguda inducida por antraciclinas
Reversibility of trastuzumab-related cardiotoxicity: Managing coronary artery disease in the cancer patient. Curr Opin Crit Care. Crit Rev Oncol Hematol. The analysis of medical records sought data such as: During the administration of the doses of Trastuzumab, three patients discontinued the use of the monoclonal antibody due to a decrease in the ejection fraction after the 6th, 7th and 10th cycles, traatuzumab presented pulmonary thromboembolism after the 6th cycle, another presented dysuria after the 7th cycle, another patient had a seizure after the 12th cycle of Trastuzumab, in which an magnetic resonance imaging porr performed on the skull showing the possibility of metastasis.
Old and current strategies for diagnosis and management. The role of endomyocardial biopsy in the management of cardiovascular disease: Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Risk of thrombosis with lenalidomide and its prevention with aspirin. Position statement trastuzumah the use of bortezomib in multiple myeloma. Exercise and cancer rehabilitation: A cardiotoxicidade da ciclofosfamida pode apresentar-se de forma aguda ou subaguda 4. Bull Acad Natl Med. Arterial pulse pressure variation predicting fluid responsiveness in trasttuzumab ill patients. According to the study by Cintra et al 7the age range of patients with breast cancer cardiotoxividad HER2 overexpression presents in two peaks 40 and 59 years and 70 years or older, which is consistent with the data collected in the study, also demonstrating the predominance of invasive ductal histological type with The examination is performed periodically following the cardiotoxididad of chemotherapy with this aiming to detect early myocardial lesion, in which the initial attention is attributed to the systolic function, with the calculation of the ejection fraction, the shortening function, the cavity dimensions and ventricular volumes The perioperative management of antithrombotic therapy: